News/ News/ R&D Atriva takes MEK inhibitor into phase 2 for COVID-19 Phil Taylor antiviral, Atriva Therapeutics, clinical trial, coronavirus, inflammation and immunology 0 Comment Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, Share X Atriva takes MEK inhibitor into phase 2 for COVID-19 https://pharmaphorum.com/news/atriva-takes-mek-inhibitor-into-phase-2-for-covid-19/